European Pharmaceutical Review

JULY 5, 2023

Having been originally published in 2007, then revised in 2013, this latest 2023 edition addresses evolving standards and container types. According the PDA, the standardised quality criteria in TR 43 are intended as a guidance overview for container manufacturers and for incoming container acceptance inspection at pharmaceutical companies.

Packaging 71

Packaging Documentation Pharmaceutical Companies Pharmaceutical Companies 71

pharmaphorum

AUGUST 23, 2021

The possibility of data being shared with third-parties including academic researchers and pharmaceutical companies raised concerns about whether the public is aware that they stand to lose control of private information on their physical, mental and sexual health. Now that’s been set back indefinitely. survey conducted in July.

Medical Records 89

Medical Records Documentation Pharmaceutical Companies Pharmaceutical Companies 89

The People's Pharmacy

MAY 8, 2023

There have been problems with records in the past: deceit, falsification of documents and even outright fraud. Since the start of 2013, pharmaceutical companies based in the U.S. But a whistleblower at the company reported that some of the scientists there were falsifying data. Carcinogens in Blood Pressure Meds?

FDA 72

FDA Pharmaceutical Companies Pharmaceutical Companies Medical Schools 72

Pharmaceutical Technology

OCTOBER 5, 2022

These, along with other similar claims, meant Biogen owed potential damages of $1,036,900,151 to the US and the various States, as per court documents. Ferry describes a popular solution among pharmaceutical companies. The $900 million dollar settlement was previously announced in June but has only been finalized this month.

Documentation 59

Documentation Pharmaceutical Companies Pharmaceutical Companies FDA 59

Pharmaceutical Technology

NOVEMBER 4, 2022

At the time of its publication, the document prioritised the finalisation of Brexit above all else. For the life sciences and pharmaceutical sector, the Conservative government promised £34 billion ($38.98 In a more recent report, the ABPI found that the number of Phase III industry trials fell by 48% between 2017 and 2021.

Documentation 93

Documentation Pharmaceutical Companies Pharmaceutical Companies 93

pharmaphorum

MAY 14, 2021

Practically though, there are risks of additional processes and requirements (and expense) for pharmaceutical companies. It is also possible that companies may prefer to enter the EU market through the EMA process and avoid additional processes involving the MHRA and NICE.

Documentation 59

Documentation Pharmaceutical Companies Pharmaceutical Companies 59

European Pharmaceutical Review

FEBRUARY 1, 2024

In this Q&A, he explores the trends and challenges within the cardiovascular treatment space, as well as clinical development of the company’s lead candidate obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor for lowering low-density lipoprotein-cholesterol (LDL-C) and ultimately reducing cardiovascular risk.

Documentation 73

Documentation Pharmaceutical Companies Pharmaceutical Companies 73